Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALOR-HCV: Sofosbuvir + Ribavirin in HCV Genotype 2 Veterans
NCT02128542Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sofosbuvir in hepatitis C (HCV), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event up to 12 weeks. Started Jun 2014; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02128542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128542.